XINGTON, Mass.–(BUSINESS WIRE)–Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the next development candidate in its product pipeline with the selection of CTP-692, a novel drug for adjunctive treatment of schizophrenia, a devastating, chronic illness with significant unmet need. CTP-692 is a deuterated form of D-serine, an endogenous, required co-agonist of the N-methyl-D-aspartate (NMDA) receptor. NMDA receptor hypofunction is believed to contribute to the pathophysiology of schizophrenia and enhancement of D-serine levels is believed to benefit individuals with schizophrenia. CTP-692 is being developed as a potential adjunctive therapy to antipsychotic medicines with the potential to improve positive and negative symptoms as well as cognitive function in these patients. The Company intends to complete preclinical evaluation and advance CTP-692 into clinical development by year-end 2018.
6 Likes
Interesting.
I wondered, “what the hell is deuterium?” (Part of this d-serine, deuterium medication.)
It is heavy hydrogen.
It’s not radioactive though. And not apparently toxic in small doses.
3 Likes
Yeah, Im not to sure tbh. But i have tried d-serine before and it worked however it made me vomit so i stoped taking it after a week.
1 Like
Yeah I guess the deuterium reduces the kidney toxicity of high doses of d-serine in some way. I don’t understand the chemistry.
2 Likes